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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterised by the dysregulated expression of
many proinflammatory cytokines including tumour necrosis
factor α (TNF-α), with increased yet insufficient production
of anti-inflammatory cytokines including IL-10 [1]. The vali-
dation of TNF-α as a therapeutic target in RA has encour-
aged the investigation of signalling pathways regulating its
production by cells relevant to the pathophysiology of this
disease. One pathway known to downregulate proinflam-
matory TNF-α production and, consequently, upregulate
the anti-inflammatory cytokine IL-10 is that elicited by the
second messenger cAMP [2,3]. This pathway may there-
fore represent a good therapeutic target due to its oppos-
ing effects on TNF-α and IL-10. Previously, we and others
demonstrated that rolipram, a phosphodiesterase (PDE) IV
inhibitor, reduced the clinical and histological severity of
collagen-induced arthritis (CIA) [4,5]. These studies
APC = antigen-presenting cell; ATF-1 = activating transcription factor-1; CIA = collagen-induced arthritis; CREB = cAMP response element
binding protein; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; IC50 = median inhibitory concentration; IFN = interferon; IL =
interleukin; LPS = lipopolysaccharide; M-CSF = macrophage-colony stimulating factor; NF-κB = nuclear factor κB; PBMC = peripheral blood
mononuclear cells; PDE = phosphodiesterase; PKA = protein kinase A; PKC = protein kinase C; PMA = phorbol 12-myristate 13-acetate; RA =
rheumatoid arthritis; RA-SMC = rheumatoid arthritis synovial membrane cell; RPMI = Roswell Park Memorial Institute [medium]; Th1/Th2 = T helper
cell type 1/2; TNF-α = tumour necrosis factor α; VIP = vasoactive intestinal peptide.
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Abstract
Vasoactive intestinal peptide (VIP) is an anti-inflammatory
immunomodulatory neuropeptide with therapeutic potential
demonstrated for collagen-induced arthritis. The aim of this
study was to characterise its potential anti-arthritic effect on
human monocytes, macrophages, T cells, and rheumatoid
arthritis synovial membrane cells. Monocytes, macrophages,
and T cells derived from human peripheral blood were treated
with VIP and compared with other cAMP-elevating drugs for a
range of activating stimuli. Cytokine production was assessed
for cell cultures and, in addition, the ability of VIPs to activate
cAMP response element binding protein. VIP partially
suppressed monocyte- and macrophage-derived tumour
necrosis factor α (TNF-α) with no effect on IL-10, whereas
VIP fails to regulate IL-10 and TNF-α production by T
lymphocytes. No such modulation of cytokine profile was
observed for rheumatoid arthritis synovial membrane cells.
Elevation of intracellular cAMP, on the other hand, potently
suppressed macrophage TNF-α production and modulated T-
cell response by inhibiting TNF-α and IFN-γ. VIP’s lack of
effect on IL-10 and its slight effect on TNF-α results from
cAMP being rapidly degraded as the phosphodiesterase IV
inhibitor, rolipram, rescues cAMP-dependent activation of
cAMP response element binding protein. Interestingly,
macrophages stimulated with phorbol 12-myristate 13-
acetate/ionomycin displayed an augmented IL-10 response
upon addition of dibutyryl cAMP, with corresponding
downregulation in TNF-α, suggesting a complex interaction
between protein kinase C and protein kinase A in cytokine
regulation. In conclusion, VIP may represent an efficaceous
anti-arthritic treatment modulating macrophage and T-cell
cytokine profiles when used alongside a phosphodiesterase
inhibitor.
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demonstrated the potential for the cAMP/protein kinase A
(PKA) pathway in treatment of autoimmune diseases such
as RA.
Another stimulator of the cAMP/PKA pathway whose prin-
ciple immunomodulatory functions are anti-inflammatory is
the vasoactive intestinal peptide (VIP). VIP is a 28-amino-
acid neuropeptide belonging to the glucagon/secretin
family, found in the nervous system and in the immune
system, where it is detected in a variety of cell types
including mast cells, neutrophils, and mononuclear cells.
The effects of VIP are transduced via three known recep-
tors, VPAC1, VPAC2, and PAC1, all of which are coupled
to adenylate cyclase via heterotrimeric G proteins. In vivo,
VIP has a therapeutic effect in the CIA mouse model [6,7]
and protects from lipopolysaccharide (LPS) shock by sup-
pression of TNF-α [8,9] and nuclear factor κB (NF-κB)
activation [10]. Furthermore, in vitro studies showed that
VIP inhibits the production of proinflammatory factors
TNF-α, IL-6, IL-12 [11,12], chemokines [13,14], and nitric
oxide (NO) [15] and stimulates the production of the anti-
inflammatory cytokine IL-10 [16], most of these effects
being apparently mediated through the VPAC1 receptor.
In addition, neuropeptides such as VIP have been shown
to inhibit activities both of stimulated T cells (VIP being
described as a Th2 cytokine), effectively suppressing
T helper cell type 1 (Th1) differentiation [17] and of
macrophages [18] and to antagonise inflammatory media-
tors such as histamine, prostaglandin E2, leukotrienes, and
neurokinins [19]. The mechanism by which VIP antago-
nises LPS-induced production of proinflammatory TNF-α
and abrogates production of anti-inflammatory IL-10 is
suggested to result from a fine balance between cAMP
response element DNA binding factors where VIP
increases the phosphorylation of PKA-dependent cAMP
response element binding protein (CREB) and decreases
the phosphorylation of c-Jun N-terminal kinase-dependent
c-Jun phosphorylation, without affecting the amount of
CRE binding: changes of CRE binding complexes from
high c-Jun/low CREB (LPS treated) to low c-Jun/high
CREB (VIP treated) leads to an inhibition of TNF-α mRNA
expression, whereas the corresponding stimulation in
IL-10 gene expression is due to an increase in CRE
binding by VIP [10; reviewed in 20].
It would appear from these studies that VIP has therapeu-
tic potential based on its ability to ameliorate CIA in mice
[6,7], this effect possibly mediated by cAMP. However,
the effect of VIP on human cells and particularly on RA
synovial cells is unknown. Thus the aim of this study was
to examine the potential of VIP as a therapeutic agent in
chronic inflammatory diseases such as RA by investigating
its effects on human macrophages, T cells, and synovial
cells — all of which play an important role in the pathology
of RA — and compare the findings with murine VIP data
already published.
Materials and methods
Reagents
Capture and detection antibodies for human TNF-α, IL-10,
and IFN-γ ELISAs were purchased from Pharmingen Inter-
national, Oxford, UK. Direct colorimetric immunoassay kit
for detection of cAMP was purchased from Merck Bio-
sciences, Nottingham, UK. Macrophage-colony stimulating
factor (M-CSF) was obtained from Genetics Institute,
Boston, MA, USA. Rolipram, a PDE IV inhibitor, was a gift
from Dr Peter Scholz (Schering, Berlin, Germany). PDE-
resistant dibutyryl cAMP and forskolin, an activator of
adenylate cyclase, were purchased from Sigma, Poole,
Dorset, UK. VIP was synthesised at the Advanced
Biotechnology Centre, Imperial College School of Medi-
cine at Charing Cross Hospital, London, UK. Antibodies to
CREB and phospho-CREB were purchased from New
England Biolabs, Beverly, MA, USA. All reagents used in
these tissue-culture experiments were tested for the pres-
ence of LPS/endotoxin contamination and were found to
be below the lower level of detection of the limulus amoe-
bocyte assay (Cambrex BioScience, Wokingham, Berk-
shire, UK). In addition, rolipram, dibutyryl cAMP, forskolin,
and VIP were tested for cytotoxicity and displayed no toxi-
city at the concentrations being used in this study as
determined by (3-[4,5-dimethylhiazol-2-yl]-2,5-diphenylte-
trazolium bromide) assay and trypan blue exclusion.
Purification of T lymphocytes and monocytes
Human peripheral blood mononuclear cells (PBMCs) were
obtained by density centrifugation of human venous blood
buffy coats (purchased from the North London Blood
Transfusion Service, Colindale, UK) through Ficoll/
Hypaque (specific density 1.077 g/ml; Nycomed Pharma
AS, Oslo, Norway). The resulting PBMCs were centrifu-
gally elutriated in 1% fetal calf serum (FCS) RPMI 1640
medium in a Beckman JE6 elutriator. Lymphocyte and
monocyte purity was assessed by flow cytometric analysis
of binding of fluorochrome-conjugated anti-CD3, anti-
CD19, anti-CD14, and anti-CD45 antibodies (Becton
Dickinson, Oxford, UK). T cells obtained were routinely of
>90% purity and monocytes of >85% purity.
Differentiation of monocytes to macrophages
Peripheral blood monocytes obtained by centrifugal elutri-
ation were seeded at 1 × 106 ml–1 in assay medium in T-75
medium tissue-culture flasks. M-CSF was added to a final
concentration of 100 ng/ml. Cells were cultured for 7 days
at 37°C in a 5% CO2 humidified atmosphere. Adherent
cells were then washed twice in FCS-free RPMI 1640 and
removed from the plastic with cell-dissociation medium
(Sigma). The resulting cells were washed twice more and
resuspended in RPMI 1640/10% FCS ready for use.
Isolation of RA synovial membrane mononuclear cells
RA synovial membrane cells (RA-SMCs) were obtained
from synovial membrane tissue samples provided by the
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Rheumatology Clinic and the Department of Muscu-
loskeletal Surgery, Charing Cross Hospital, London, UK.
All patients gave their signed consent, and ethical
approval was obtained from the Riverside Research Ethics
Committee, London. Patients met the American College of
Rheumatology (ACR) 1987 revised criteria for RA. Syn-
ovial membranes obtained were from patients who failed
to respond to anti-rheumatic regimens currently available
in the rheumatology clinic and will be discussed later in
this manuscript. In brief, tissue was cut into small pieces
and digested in medium containing 0.15 mg/ml DNAse
type I (Sigma) and 5 mg/ml collagenase A (Roche, Lewes,
Sussex, UK) for 1 to 1.5 hours at 37°C. Cell debris was
excluded by passing cells through a nylon mesh, and cells
were then washed and collected in RPMI–10% FCS at
1 × 106 cells/ml and used immediately for spontaneous
cytokine production by RA-SMCs.
Detection of intracellular cAMP
A number of signals are known to stimulate the production
of cAMP through the action of adenylate cyclase convert-
ing ATP to cAMP. Intracellular cAMP was measured using
a colorimetric direct immunoassay in accordance with the
manufacturer’s instructions. Briefly, 5 × 105 monocytes/
macrophages were incubated with test reagents, and then
cells were lysed in 0.1 N HCl at room temperature for
approximately 10 min. In the capture microtitre plate pro-
vided, 100 µl lysate and controls were added per well
along with 50 µl conjugate and 50 µl antibody solution and
incubated for 2 hours at room temperature on a plate
shaker. The plate was then emptied and washed three
times in wash buffer provided. Colour development was
detected using 200 µl pNpp substrate solution and incu-
bated for 1 hour at room temperature and stopped by the
addition of 50 µl stop solution. These assays were read
and quantified on a Labsystems Multiscan Bichromatic
plate reader at 405 nm and analysed with a Deltasoft II
programme (BioMetallics Inc, Princeton, NJ, USA). The
minimal sensitivity of the assay was 0.078 pmol/ml cAMP.
All results are expressed as the mean concentration of
cAMP obtained per condition.
Cytokine determination by ELISA
Sandwich ELISAs were used to measure human IL-10,
TNF-α, and IFN-γ. In the IL-10 assay, the anti-IL-10 mono-
clonal antibody 9D7 was used as the capture antibody,
and biotinylated 12G8 was used as the detection anti-
body. The ELISA was performed as previously described,
with a standard curve of recombinant human IL-10 from
10,000 to 13 pg/ml [21]. TNF-α ELISA was carried out as
described using 61E71 as the coating antibody and a
rabbit polyclonal anti-TNF-α antibody as the detection
antibody. This polyclonal anti-TNF-α antibody was in turn
detected by a horseradish-peroxidase-conjugated goat
anti-rabbit IgG(H+L) (Jackson ImmunoResearch, West
Grove, PA, USA). The standard curve of recombinant
human TNF-α covered the range of 20,000 to 8pg/ml [22].
In addition, human IFN-γ ELISA was carried out in accor-
dance with the manufacturer’s specifications (PharMingen
International, Oxford, UK). These ELISAs were quantified
by tetramethylbenzide dichloride activity in response to the
horseradish peroxidase conjugate and read on a Labsys-
tems Multiscan Bichromatic plate reader at 450nm and
analysed with the Deltasoft II programme (BioMetallics).
The minimal sensitivity of the ELISAs were 8pg/ml for
human TNF-α and 13–40pg/ml for the human IL-10 and
IFN-γ ELISAs. All results are expressed as the mean con-
centration of cytokine± SD obtained per condition.
Western blot analysis of phospho-CREB
Macrophages were seeded at 5 × 106 cells/ml in 24-well
plates in RPMI 1640/10% FCS. To inhibit phosphodi-
esterase activity prior to VIP treatment, macrophages were
pretreated for 1 hour with 10 µM rolipram and then stimu-
lated for 30 min with 10 µM VIP before harvesting of cell
lysates. The stimulation time was previously defined in our
laboratory as optimal for activation of CREB. After stimula-
tion, cells were lysed on ice for 15 min in lysis buffer (1%
NP-40, 200 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol,
1 mM Na3VO4, 1 mM NaF, 1 mM phenylmethylsulfonyl fluo-
ride, 10 µg/ml leupeptin, 10 µg/ml pepstatin, and 10 µg/ml
aprotinin). Lysed samples (10 µg) were separated by elec-
trophoresis on a 10% SDS–polyacrylamide gel and trans-
ferred to a nitrocellulose membrane. Phosphorylated
proteins were detected using antibodies raised against
phospho-CREB followed by anti-rabbit horseradish peroxi-
dase conjugate and enhanced chemiluminescence (ECL;
Amersham Pharmacia Biotech UK Ltd, Little Chalfont,
Buckinghamshire, UK). Protein bands were visualised by
autoradiography using Hyperfilm (Amersham Pharmacia
Biotech UK).
Statistical analysis
Comparison of data was assessed using GraphPad Prism
version 3.0 (GraphPad Software Inc, San Diego, CA,
USA). Statistical differences were determined with Stu-
dent’s t-test. Differences were regarded as significant
when *P < 0.05, **P < 0.01, or ***P < 0.001.
Results
VIP, rolipram, and dibutyryl cAMP suppress 
LPS-induced monocyte TNF-α production without
upregulating IL-10
First, we compared the effects of VIP, rolipram, and dibu-
tyryl cAMP on the production of TNF-α and IL-10 by
monocytes. Spontaneous production of IL-10 and TNF-α
by monocytes could not be detected; cytokine production
was induced, however, by addition of LPS (control
samples). VIP dose-dependently inhibited LPS-induced
TNF-α production from LPS-stimulated control levels of
508 ± 65 pg/ml to 226 ± 11 (P = 0.021) at 10–6 M with a
median inhibitory concentration (IC50) value of 1.45 nM
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(range 0.83 to 2 nM for n = 4 experiments) (Fig. 1b). In con-
trast, the anti-inflammatory cytokine IL-10 is not signifi-
cantly regulated by VIP: the LPS-stimulated control value
was 420 ± 41 pg/ml, versus 371 ± 82 pg/ml at 10–5 M
(Fig. 1a). The effects of VIP are reported to be mediated
by the cAMP/PKA pathway — a pathway that potently reg-
ulates TNF-α and IL-10 production. Thus, the contribution
of cAMP to cytokine production was investigated using
the PDE IV inhibitor rolipram and the PDE-resistant dibu-
tyryl cAMP. Inhibition of PDE by rolipram had little effect
on LPS-induced IL-10 production (Fig. 1c), whereas
rolipram potently inhibited LPS-stimulated TNF-α produc-
tion (IC50 = 350 nM) (Fig. 1d). In addition, LPS-stimulated
TNF-α production was potently inhibited by dibutyryl
cAMP (IC50 = 4 µM) (Fig. 1f). IL-10, on the other hand, was
only partially suppressed: control 747 ± 13 pg/ml, versus
428 ± 8 pg/ml at 100 µM (Fig. 1e). This effect on IL-10 pro-
duction was thought to be a consequence of TNF-α sup-
pression, as endogenous TNF-α has been demonstrated
to regulate LPS-induced IL-10 production in monocytes
[23]. In fact, the addition of a neutralising anti-TNF-α anti-
body only served to inhibit IL-10 by approximately 30%;
the simultaneous addition of VIP had no effect on IL-10
production. Control experiments were carried out to deter-
mine the effectiveness of VIP on the basis of its ability to
potently inhibit LPS-induced monocyte production of IL-8;
in our hands, VIP suppressed IL-8 production, resulting in
a mean IC50 = 11 nM for three separate experiments (range
2 to 25 nM; data not shown).
VIP, rolipram, and dibutyryl cAMP suppress LPS-
induced macrophage TNF-α production without
upregulating IL-10
VIP has been shown to differentially modulate proinflamma-
tory and anti-inflammatory cytokine production by murine
macrophages [8,9,12,13,16]. Thus it was desirable to
compare human monocytes with monocyte-derived
macrophages obtained by M-CSF treatment of peripheral
blood monocytes, this cell type being more representative
of tissue macrophages present in the rheumatoid joint.
Again, spontaneous cytokine production could not be
detected in the absence of an activating stimulus. The
effects of VIP on macrophage IL-10 and TNF-α were com-
parable and not significant. VIP inhibited LPS-induced
TNF-α (Fig.2b), with IC50 values ranging between 7 and
50nM for n=7 experiments, and partially suppressed IL-10
production (Fig.2a). This trend was repeated by treatment
with rolipram and dibutyryl cAMP, where LPS-induced
TNF-α production was suppressed, resulting in values of
IC50 =50nM (Fig.2d) and IC50 =2.5µM (Fig.2f), respec-
tively. LPS-induced IL-10 production was partially sup-
pressed by rolipram (Fig.2c) and dibutyryl cAMP (Fig.2e).
This partial suppression of IL-10 was independent of
endogenous TNF-α expression, as blockade by anti-TNF-α
antibodies failed to abrogate this partial suppression by VIP,
as did the addition of exogenous TNF-α (Table 1). LPS-
induced macrophage IL-10 production was suppressed by
12.7% by 10–6 M VIP, which, upon neutralisation of TNF-α,
apart from the expected decrease in IL-10 production
Arthritis Research & Therapy    Vol 5 No 6 Foey et al.
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Figure 1
VIP suppresses LPS induction of monocyte TNF-α but has no effect on IL-10 production. Fresh, elutriated human monocytes were plated out at
2 × 105 cells per well in a U-bottomed 96-well plate and pretreated with VIP (a,b), rolipram (c,d), or dibutyryl cAMP (e,f) for 1 hour prior to
stimulation with 1 ng/ml LPS and incubated for 24 hours at 37°C in a 5% CO2 humidified atmosphere, after which time supernatants were
harvested and assayed for TNF-α and IL-10 by ELISA. Data are mean cytokine levels in pg/ml of triplicate culture supernatants ± SD, showing a
representative of n = 4 replicate experiments. *P < 0.05; **P < 0.01; ***P < 0.001. LPS, lipopolysaccharide; TNF-α, tumour necrosis factor α; VIP,
vasoactive intestinal peptide.
(48%), resulted in 17.8% suppression at the same concen-
tration of VIP. Exogenous TNF-α had little effect on IL-10
production and the lack of modulation by VIP. LPS-induced
IL-10 was partially modulated by 10–6 M VIP (12.7% sup-
pression), which upon addition of exogenous TNF-α
resulted in 8.4% suppression by VIP. Conversely, VIP sup-
pressed LPS-induced macrophage TNF-α by 55%, which
upon neutralisation of IL-10, apart from the expected
increase in TNF-α production (2.17-fold), resulted in 28%
suppression at the same concentration of VIP (Table 2).
Exogenous IL-10 suppressed total TNF-α production by
91% but had no effect on VIP modulation, which resulted in
a 26% suppression (Table 2). The effect of IL-10 neutralisa-
tion or addition of exogenous IL-10 significantly modulated
LPS-induced TNF-α production by macrophages. However,
modulation of TNF-α production by VIP was not significantly
different in these groups; a separate set of data showed
suppressions of 26%, 36%, and 58%, versus 55%, 28%,
and 26% for control, endogenous, and exogenous IL-10,
respectively. Control experiments were carried out to deter-
mine the effectiveness of VIP based on its ability to potently
inhibit LPS-induced monocyte production of IL-8; in our
hands, VIP suppressed macrophage IL-8 production, result-
ing in a mean IC50 =38nM for three separate experiments
(range 9 to 79nM).
The lack of any great effect of VIP on monocyte-derived
macrophages and monocytes themselves led us to
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Table 1
TNF-α fails to modulate VIP regulation of LPS-induced
macrophage IL-10
IL-10
Treatment Control + VIP
Control 2182 ± 317.7 1904 ± 255.7 (12.7%)
Anti-TNF-α 1123 ± 23.92 922.7 ± 49.93 (17.8%)
Exogenous TNF-α 1481 ± 494.6 1606 ± 906.3 (–8.4%)
Macrophage-colony stimulating factor (M-CSF)-primed monocyte-
derived macrophages, plated at 1×105 cells/well, were stimulated with
1ng/ml LPS in the presence or absence of 10–6 M VIP. TNF-α
modulation of VIP regulation of IL-10 production was assessed by
addition of 10µg/ml neutralising anti-TNF-α (A2) or 10ng/ml TNF-α.
Results with an isotype-matched control antibody did not differ
significantly from the control sample presented in this table. The resulting
cultures were incubated for 24 hours at 37°C in a 5% CO2 humidified
atmosphere, after which time supernatants were harvested and assayed
for IL-10 by ELISA. Data are mean IL-10 levels in pg/ml and percentage
suppression by VIP in parentheses of triplicate culture supernatants± SD,
showing a representative of n=3 experiments. LPS, lipopolysaccharide;
TNF-α, tumour necrosis factor α; VIP, vasoactive intestinal peptide.
Figure 2
VIP suppresses LPS induction of macrophage TNF-α with little effect on IL-10 production. Human-monocyte-derived macrophages were plated out
at 1 × 105 cells per well in a flat-bottomed 96-well plate and pretreated with VIP (a,b), rolipram (c,d) or dibutyryl cAMP (e,f) for 1 hour prior to
stimulation with 1 ng/ml LPS and were incubated for 24 hours at 37°C in a 5% CO2 humidified atmosphere, after which time supernatants were
harvested and assayed for TNF-α and IL-10 by ELISA. Data are mean cytokine levels in pg/ml of triplicate culture supernatants ± SD, showing a
representative of n = 7 replicate experiments. Western blot analysis of activated phospho-CREB (g) shows VIP modulation in the presence or
absence of PDE inhibition. Lane 1, LPS-stimulated macrophage control; 2, LPS-stimulated macrophage + 10–6 M VIP; 3, LPS-stimulated
macrophage + 10–6 M VIP + 10 µM rolipram. Data are representative of n = 3 replicate experiments. *P < 0.05; **P < 0.01; ***P < 0.001. CREB =
cAMP response element binding protein; LPS, lipopolysaccharide; P-ATF, activating transcription factor-1; P-CREB, phospho-CREB; rol., rolipram;
TNF-α, tumour necrosis factor α; VIP, vasoactive intestinal peptide.
postulate that there was an endogenous phosphodi-
esterase activity intrinsic to these human cells. This was
confirmed by the inability of VIP to activate/phosphorylate
CREB, a downstream effector molecule to the cAMP-
dependent PKA pathway, in M-CSF-treated macrophages
(Fig. 2g, lane 2). Of particular interest is the fact that simul-
taneous addition of VIP and the PDE IV inhibitor rolipram
restored activation of CREB (Fig. 2g, lane 3), suggesting
that in the absence of a PDE inhibitor these cells quickly
and efficiently break down cAMP produced in response to
VIP. Rolipram on its own inhibits PDE IV activity (cAMP
breakdown) but does not stimulate cAMP production and
as such was not included in this phospho-western result.
This control, however, failed to activate CREB by phos-
phorylation of residue Ser 133 on all blots tested. Of par-
ticular interest, however, is the observation that activating
transcription factor-1 (ATF-1) is activated by LPS (ATF-1
is also recognised by the CREB antibody used) (lane 1),
an effect that is abrogated in the presence of VIP (lane 2),
and that the combination of VIP and rolipram activates
both CREB and ATF-1 upon LPS stimulation (lane 3).
VIP fails to modulate T-cell production of IL-10, TNF-α,
and IFN-γ
T cells are thought to play a role in perpetuating the
chronic inflammatory response in the rheumatoid joint.
T cells in the rheumatoid joint are in close proximity to
macrophages and can regulate the activation of such
cells. However, macrophages can themselves regulate
T-cell functions. Thus it was desirable to investigate the
regulatory role of VIP on activated T lymphocytes. Phorbol
12-myristate 13-acetate (PMA)/ionomycin-stimulated T cells
produced IL-10 and TNF-α over a 24-hour culture period.
The addition of VIP, however, failed to modulate the pro-
duction of either IL-10 (Fig. 3a) or TNF-α (Fig. 3b). In com-
parison, treatment of PMA/ionomycin-stimulated T cells
with dibutyryl cAMP failed to modulate IL-10 production
(Fig. 3d) but modestly suppressed TNF-α production
(IC50 = 8.8 µM) (Fig. 3e).
In addition, VIP has been shown to modulate T-cell func-
tion in the murine system of CIA, shifting a Th1 cytokine
response to a Th2-like response [6]. We investigated this
modulation in the context of the human T cells stimulated
by PMA/ionomycin. Unlike its effect in the murine system,
VIP failed to modulate human T-cell activity. PMA/iono-
mycin-induced T-cell IFN-γ production was not signifi-
cantly affected by VIP (Fig. 3c). Unlike VIP however,
elevation of intracellular cAMP did modulate IFN-γ produc-
tion. The addition of cell-permeable dibutyryl cAMP sup-
pressed IFN-γ production from PMA/ionomycin-stimulated
T cells (IC50 = 9 µM) (Fig. 3f). In a separate set of experi-
ments, IFN-γ was also suppressed by the adenylate
cyclase activator forskolin (data not represented graphi-
cally) from PMA/ionomycin-stimulated control levels of
6963 ± 230 pg/ml to 5691 ± 265 pg/ml (P = 0.027) and
4968 ± 372 pg/ml (P = 0.025) at concentrations of 10 µM
and 20 µM respectively (IC50 = 6 µM), and by rolipram, the
PDE IV inhibitor, from 6963 ± 230 pg/ml to 2685 ± 204
(P = 0.002) and 2262±94 (P=0.002) at 1µM and 10µM
respectively (IC50 =2µM) (data not represented graphically).
In addition, these data were reproducible for concanavalin-
A-stimulated T cells from human peripheral blood.
cAMP modulates PMA/ionomycin stimulated
macrophage cytokine profile
Unlike its effect in the murine system, elevation of cAMP in
LPS-activated macrophages failed to augment the human
anti-inflammatory IL-10 response but potently inhibited the
TNF-α response. In this study, macrophages were stimu-
lated by PMA/ionomycin activating protein kinase C (PKC).
Elevation of intracellular cAMP, by the addition of the phos-
phodiesterase-resistant dibutyryl cAMP, augmented IL-10
production with a corresponding decrease in TNF-α pro-
duction (Fig.4). Dibutyryl cAMP augmented IL-10 produc-
tion (ED50 =6.4 µM; Fig.4a) whereas TNF-α production
was inhibited (IC50 =6 µM; Fig.4b). These data were con-
firmed by use of the PDE inhibitor rolipram and the adeny-
late cyclase activator forskolin. Rolipram and forskolin
augmented IL-10 to 779% and 767% whereas TNF-α was
inhibited by 50% and 55% at 100 µM and 10 µM, respec-
tively (data not shown). VIP failed to modulate IL-10 pro-
duction on its own but could in the presence of rolipram
(see paragraph below and Fig.6a below). In addition, the
phosphodiesterase-resistant dibutyryl cAMP costimulated
the downstream effector molecule to the cAMP-dependent
PKA pathway, CREB, which was phosphorylated upon
PKC activation by PMA/ionomycin (Fig.4c, lane 3). Neither
stimulus, on its own, activated CREB.
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Table 2
IL-10 fails to modulate VIP regulation of LPS-induced
macrophage TNF-α
TNF-α
Treatment Control +VIP
Control 1400 ± 62.02 630.3 ± 61.55 (55%)
Anti-IL-10 3041 ± 624.9 2195 ± 224.9 (28%)
Exogenous IL-10 119.5 ± 6.944 88.26 ± 14.48 (26%)
Macrophage-colony stimulating factor (M-CSF)-primed monocyte-derived
macrophages, plated at a density of 1×105 cells/well, were stimulated by
1ng/ml LPS in the presence or absence of 10–6 M VIP. IL-10 modulation
of VIP regulation of TNF-α production was assessed by addition of
10µg/ml neutralising anti-IL-10 (9D7) or 10ng/ml IL-10. Results with an
isotype-matched control antibody did not differ significantly from the
control sample presented in this table. The resulting cultures were
incubated for 24 hours at 37°C in a 5% CO2 humidified atmosphere, after
which time supernatants were harvested and assayed for TNF-α by
ELISA. Data are mean TNF-α levels in pg/ml and percentage suppression
by VIP in parentheses of triplicate culture supernatants±SD, showing a
representative of n=3 experiments. LPS, lipopolysaccharide; TNF-α,
tumour necrosis factorα; VIP, vasoactive intestinal peptide.
Macrophages have a high endogenous PDE IV activity:
VIP induction of cAMP is augmented by rolipram
VIP induces the release of cAMP. We have suggested
earlier in this article that cAMP levels are not likely to
persist, because of a high endogenous activity of PDE IV
in macrophages. This has been avoided by the utilisation
of the PDE-resistant form of cAMP, dibutyryl cAMP, which
previously potently suppressed macrophage TNF-α pro-
duction and specifically augmented PMA/ionomycin-stim-
ulated macrophage IL-10 production. We wished to
investigate VIP regulation of cAMP levels in monocytes
and macrophages upon stimulation by LPS and PMA/ion-
omycin. VIP regulation of cAMP was augmented by the
PDE IV inhibitor rolipram, where LPS-stimulated mono-
cytes resulted in 0.833 pmol/ml and PMA/ionomycin stim-
ulation resulted in 0.367 pmol/ml (see Fig. 5a). LPS- and
PMA/ionomycin-stimulated macrophages, on the other
hand, produced much higher (10- to 20-fold) levels of
cAMP upon treatment with VIP and rolipram
(11.67 pmol/ml and 16.60 pmol/ml respectively; see
Fig. 5b) compared with monocytes, a finding that would
confirm the higher level of endogenous PDE activity
observed in macrophages. Thus, in the presence of high
endogenous PDE activity, VIP is incapable of maintaining
a prolonged elevation of cAMP, which would suggest the
relatively modest effect of VIP on TNF-α production when
compared with PDE-resistant dibutyryl cAMP and the dis-
tinct lack of modulation of IL-10 production. Rolipram
treatment alone failed to exhibit any induction of intracellu-
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Figure 3
VIP fails to suppress PMA/ionomycin-stimulated T-cell induction of
TNF-α, IL-10, and IFN-γ production. Fresh, elutriated human
T lymphocytes were plated out at 1 × 105 cells per well in a
U-bottomed 96-well plate and pretreated with VIP (a,b,c), or dibutyryl
cAMP (d,e,f) for 1 hour prior to stimulation with 50 ng/ml PMA and
0.5 µg/ml ionomycin and incubated for 24 hours at 37°C in a 5% CO2
humidified atmosphere, after which time supernatants were harvested
and assayed for IL-10 (a,d), TNF-α (b,e), and IFN-γ (c,f) by ELISA. Data
are mean cytokine levels in pg/ml of triplicate culture
supernatants ± SD, showing a representative of n = 4 replicate
experiments. *P < 0.05; **P < 0.01. PMA, phorbol 12-myristate
13-acetate; TNF-α, tumour necrosis factor α; VIP, vasoactive intestinal
peptide.
Figure 4
Elevation of intracellular cAMP augments PMA/ionomycin-stimulated
macrophage IL-10 production and suppresses TNF-α. Human-
monocyte-derived macrophages were plated out at 1 × 105 cells per
well in a flat-bottomed 96-well plate and pretreated with dibutyryl
cAMP for 1 hour prior to stimulation with 50 ng/ml PMA and 0.5 µg/ml
ionomycin and incubated for 24 hours at 37°C in a 5% CO2 humidified
atmosphere, after which time supernatants were harvested and
assayed for IL-10 (a) and TNF-α (b) by ELISA. Data are mean cytokine
levels in pg/ml of triplicate culture supernatants ± SD, showing a
representative of n = 7 replicate experiments. Western blot analysis of
activated phospho-CREB (c) shows cAMP modulation of CREB upon
macrophage stimulation by PMA/ionomycin. Lane 1, macrophage
control; 2, macrophage + PMA/ionomycin; 3, macrophage + PMA/
ionomycin + cAMP. Data are representative of n = 3 replicate
experiments. *P < 0.05; **P < 0.01; ***P < 0.001. CREB, cAMP
response element binding protein; P-ATF, activating transcription
factor-1; P-CREB, phospho-CREB; PMA, phorbol 12-myristate 13-
acetate; TNF-α, tumour necrosis factor α.
lar cAMP over that observed for stimulation controls,
which confirms the finding that VIP induces a cAMP-
dependent response. Positive controls were measured for
addition of dibutyryl cAMP, where PMA/ionomycin-stimu-
lated macrophages resulted in intracellular levels of
28.18 pmol/ml and LPS-stimulated macrophages,
21.38 pmol/ml, versus monocyte levels of 39.81 pmol/ml
and 89.13 pmol/ml, respectively.
Rolipram and VIP augment IL-10 production in a
stimulus- and cell-specific manner
Elevation of intracellular cAMP by the phosphodiesterase-
resistant dibutyryl cAMP augments production of IL-10 by
PMA/ionomycin-stimulated macrophages. The lack of aug-
mentation of IL-10 production by VIP is suggested by a
short-lived elevation in cAMP as a result of high endoge-
nous PDE activity. Here, we have investigated VIP modula-
tion of cytokine production in the presence of rolipram, an
inhibitor of PDE IV activity. Our results demonstrate both
stimulus- and cell-type-specific responses to VIP in the
presence of rolipram. The addition of VIP and rolipram on
their own or in combination in the absence of an activating
stimulus failed to induce cytokine production. VIP aug-
mented macrophage IL-10 production when stimulated by
PMA/ionomycin in the presence of rolipram (Fig. 6a). This
was not the case, however, when macrophages were
stimulated with LPS; LPS-induced IL-10 production was
unaffected by rolipram alone or rolipram+VIP (Fig. 6b). In
addition, stimulated T cells also failed to show an augmen-
tation of IL-10 production upon treatment by VIP and
rolipram (Fig. 6c). On the other hand, rolipram augmented
VIP suppression of TNF-α production in a cell-nonspecific
and stimulation-nonspecific manner, as observed for
PMA/ionomycin- and LPS-stimulated macrophages and
concanavalin-A-stimulated T cells (data not shown).
VIP fails to modulate spontaneous IL-10 and TNF-α
production by RA-SMCs
To investigate the role of VIP as a modulator of cytokine
production in RA, VIP was added to dissociated, cultured
RA-SMCs and spontaneous cytokine production was
assessed. In this study, VIP failed to modulate the sponta-
neous production of IL-10 and TNF-α (Fig. 7a,b). At the
maximal concentration used, VIP suppressed IL-10 by 4%
and TNF-α by 18.9%. In comparison, the effect of the
PDE-resistant dibutyryl cAMP was also investigated, mim-
icking the effect of both VIP and rolipram and resulting in
stable PDE-resistant and prolonged cAMP. Elevation of
cAMP effectively suppressed spontaneous TNF-α produc-
tion with relatively little effect on IL-10 production by RA-
SMCs (Fig. 7c,d). Dibutyryl cAMP suppressed
spontaneous TNF-α production by 36% and 46% at con-
centrations of 100 and 1000 µM, respectively
(IC50 = 20 µM). Spontaneous IL-10 production was par-
tially suppressed by 8% and 15% at 10 µM and 100 µM,
respectively. The lack of responsiveness to VIP and
effects of cAMP were reproducible between patient
samples; however, patient variability exists for sponta-
neous cytokine production: mean TNF-α production
486 pg/ml (range 70 to 1047 pg/ml), mean IL-10 produc-
tion 529 pg/ml (range 199 to 1064 µpg/ml).
Discussion
In a murine model of arthritis (CIA), VIP has been
described as a potent anti-inflammatory mediator effec-
tively reducing paw swelling, clinical score, and histologi-
cal severity of disease [6,7]. This neuropeptide
downregulates macrophage and T-cell function as well as
modulating T-cell phenotype by altering Th1/Th2 balance
in favour of Th2-like cells. There are no such compelling
data for the efficacy of VIP in human tissues. The data pre-
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Figure 5
Macrophages have a high endogenous PDE IV activity: VIP induction
of cAMP is augmented by rolipram. Human monocytes (a) and
monocyte-derived macrophages (b) were plated out at 5 × 105 cells
per well in a flat-bottomed 24-well plate and simultaneously treated
with 10–6 M VIP, or VIP in the presence of 10 µM rolipram, and
stimulated with 50 ng/ml PMA and 0.5 µg/ml ionomycin or 1 ng/ml LPS
and incubated for 24 hours at 37°C in a 5% CO2 humidified
atmosphere, after which time cell lysates were harvested and assayed
for cAMP by immunoassay. Data are mean cAMP levels in pmol/ml of
duplicate culture supernatants, showing a representative of n = 2
replicate experiments. Iono, ionomycin; LPS, lipopolysaccharide; PDE,
phosphodiesterase; PMA, phorbol 12-myristate 13-acetate; Rol,
rolipram; VIP, vasoactive intestinal peptide.
sented in this paper would argue against VIP alone being
a useful therapeutic agent in the treatment of human
chronic inflammatory disorders such as RA, because the
peptide failed to significantly modulate in vitro TNF-α
IL-10 expression by human cells. The lack of effect of VIP
in monocyte/macrophage cultures stimulated with LPS
may have been due to a high level of endogenous intrinsic
phosphodiesterase activity, resulting in a short-lived cAMP
in these cell types. This question was addressed by the
use of rolipram to inhibit PDE IV and dibutyryl cAMP,
which is resistant to PDEs. The treatment of macrophages
with VIP in the presence of rolipram facilitated activation of
CREB but did not augment IL-10 cytokine production. In
addition, this lack of sensitivity of cells to VIP is not as a
result of a window of opportunity of action. VIP was added
1 hour prior to stimulation. However, some reports have
described VIP to be a more effective anti-inflammatory
agent if it is administered at the same time as or after stim-
ulation; addition of VIP to cultures 1 hour before, simulta-
neously with, or 2 hours after stimulation showed no
significant differences to TNF-α/IL-10 ratios in this study.
The effect of VIP in modulating T-cell function was
observed by Delgado and colleagues and by Williams and
colleagues, in studies in which murine lymph node cells
from CIA mice demonstrated a shift in ratio of IFN-γ/IL-5,
from Th1 in favour of a Th2 profile [6,7]. We wished to
investigate this modulation of a Th1-driven response
(IFN-γ production) in the context of stimulated human
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Figure 6
Rolipram and VIP augment IL-10 production in a stimulus- and cell-
specific manner. Human-monocyte-derived macrophages and T cells
were plated out at a density of 1 × 105 cells per well in a flat-bottomed
96-well plate and pretreated with 10 µM rolipram and indicated
concentrations of VIP for 1 hour prior to stimulation. Macrophages
were stimulated with (a) 50 ng/ml PMA and 0.5 µg/ml ionomycin or 
(b) 1 ng/ml LPS, and T cells were stimulated with (c) 10 µg/ml
concanavalin A and incubated for 24 hours at 37°C in a 5% CO2
humidified atmosphere, after which time supernatants were harvested
and assayed for IL-10 by ELISA. Data are mean cytokine levels in
pg/ml of triplicate culture supernatants ± SD, showing a representative
of n = 3 replicate experiments. **P < 0.01; ***P < 0.001. Iono,
ionomycin; LPS, lipopolysaccharide; PMA, phorbol 12-myristate 13-
acetate; Rol, rolipram; VIP, vasoactive intestinal peptide.
Figure 7
VIP fails to modulate spontaneous IL-10 and TNF-α production by RA-
SMCs. RA-SMCs were plated out at 2 × 105 cells per well in a flat-
bottomed 96-well plate and treated with VIP (a,b) or PDE-resistant
dibutyryl cAMP (c,d) for 24 hours at 37°C in a 5% CO2 humidified
atmosphere, after which time supernatants were harvested and
assayed for spontaneous production of IL-10 (a,c) and TNF-α (b,d) by
ELISA. Data are mean cytokine levels in pg/ml of triplicate culture
supernatants ± SD, showing a representative (one patient) of n = 3
replicate experiments for a total of four patient samples. *P < 0.05.
PDE, phosphodiesterase; RA-SMC, rheumatoid arthritis synovial
membrane cell; VIP, vasoactive intestinal peptide.
T cells. Indeed, VIP failed to modulate IFN-γ. However, ele-
vation of intracellular cAMP by rolipram, dibutyryl cAMP,
and forskolin dose-dependently suppressed IFN-γ and
TNF-α production. This would suggest that VIP activation
of the cAMP pathway is not involved in T-cell IFN-γ pro-
duction or that the cAMP is rapidly degraded by an active
phosphodiesterase present in the cell. This T-cell unre-
sponsiveness to VIP with respect to production of TNF-α,
IL-10, and IFN-γ is not a consequence of PMA/ionomycin
stimulation, as PHA and concanavalin A also failed to
exhibit VIP responsiveness. Alternatively, reports thus far
describing modulation of T-cell activity have used PBMCs
and lymph node cells, whereas our present studies used
purified T cells, which appear relatively insensitive to VIP.
We suggest that the modulatory effect of VIP on T-cell
cytokine production is indirect, through the regulation of
effector functions of antigen-presenting cells (APCs). The
role of Th differentiation is likely to play a role where VIP
has been described to bias the Th1/Th2 balance in favour
of Th2, thus indirectly modulating T-cell cytokine produc-
tion [17]. The data presented in this paper focus on
mature human T-cell modulation by VIP, which has no
direct effect on cytokine production; the confirmation of an
effect of VIP on T-cell differentiation warrants further inves-
tigation in the human system using naïve T cells from cord
blood.
Unlike its effect in the murine system, VIP has little effect
in modulating IL-10 production by human peripheral blood
derived monocytes, macrophages, and T cells. It sup-
presses monocyte TNF-α production upon stimulation
with LPS and is less potent in M-CSF differentiated
macrophages. Results obtained with the PDE IV inhibitor
rolipram and the PDE-resistant dibutyryl cAMP suggest
that the cAMP generated is a potent inhibitor of LPS-
induced TNF-α, whereas IL-10 is relatively unaffected. The
slight inhibition of IL-10 by elevation of cAMP is thought to
be a consequence of the potent inhibition of TNF-α. The
failure of VIP to augment macrophage IL-10 production,
unlike the murine system, is likely to result from the lack of
activation/phosphorylation of CREB, a transcription factor
that is readily activated in the murine system by VIP [10].
This is likely to be due to instability of cAMP that results
from PDE activation. The combined treatment with VIP
and rolipram both activated CREB and augmented IL-10
production. In addition, VIP failed to modulate sponta-
neous IL-10 or TNF-α production by RA-SMCs. However,
spontaneous TNF-α production was suppressed by the
PDE-resistant dibutyryl cAMP. This would again suggest
that cAMP is failing to activate CREB by a mechanism
which involves high PDE activity.
Thus, VIP inhibition of TNF-α was less effective in
macrophages than in monocytes and was completely inef-
fective in RA-SMCs, which suggests that there is an
increase in PDE activity during differentiation. One point of
note regarding the responsiveness of macrophages and
RA-SMCs to VIP is that the effective doses are higher
than in earlier reports. In addition to the PDE IV activity,
this might be explained by modulation of expression of the
VIP receptors (VPAC1 and VPAC2) on these cells.
Indeed, in the case of RA-SMCs, it is possible that the
method of isolation from synovial membrane tissue might
downregulate VIP-receptor expression. Additionally, this
could be accounted for by the drug regimen encountered
by the patient, where patient tissue obtained by surgery
results from the failure to respond to treatments given,
decreasing sensitivity to VIP through downmodulation of
the receptors. Monocytes, however, were more sensitive
to VIP than macrophages, and as such would also
suggest that maturation might influence VIP responsive-
ness through modulation of receptor expression. The rela-
tive expression of these receptors is currently under
investigation.
Alternatively, this slight discrepancy between effective
doses of VIP (IC50) in our data and data already published
may result from both different methods of isolation and dif-
ferent cell populations. Our studies use highly purified
cells obtained by the centrifugal elutriation of PBMCs,
resulting in >90–95% monocytes and T cells that are not
prestimulated in any way as a consequence of the purifica-
tion protocol. Reports in the literature on human cells
describe VIP to potently suppress TNF-α (IC50 approxi-
mately 20 nM) in whole blood cultures and purified mono-
cytes, where monocytes were separated by clumping and
adherence, activating stimuli which may prime VIP
responses [24]. In addition, VIP suppresses LPS-induced
monocyte IL-8 production (IC50 approximately 0.1 M) [14]
and LPS-induced peripheral blood mononuclear cell
TNF-α production, its potency and overall effect being
dependent on the age of the subject where VIP inhibited
LPS-induced TNF-α in young patients but stimulated
TNF-α in older subjects [25]. Thus, responsiveness to VIP
can be regulated by many factors, including cell type and
differentiation status, method of purification, activation
stimulus encountered, age of subject, and drug regimens
encountered by donors.
Although VIP activity has been documented to be regu-
lated in a cAMP-dependent manner, there are additional
cAMP-independent mechanisms capable of transducing
VIP function. One such mechanism involves the inhibition
of NF-κB, a crucial factor for the expression of inflamma-
tory mediators such as TNF-α [26]. Thus, the effects of
VIP can be explained not only through the cAMP/PKA
pathway. This dichotomy in mechanisms of VIP action may
explain differential regulation of proinflammatory and anti-
inflammatory cytokines: inhibition of NF-κB suppresses
TNF-α production, whereas activation of the cAMP/PKA/
CREB pathway in the presence of low endogenous PDE
activity not only suppresses TNF-α but also positively reg-
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ulates IL-10 production. Further investigation into the
cAMP-dependent mechanism led to an interesting obser-
vation which described ATF-1 activation by LPS-stimu-
lated macrophages whereas CREB was not activated; the
addition of VIP abrogated this activation. The combined
treatment of VIP+rolipram, however, resulted in activation
of both CREB and ATF-1 upon LPS stimulation. It is possi-
ble that, in addition to NF-κB, the suppressive effect of
VIP on TNF-α production is achieved through inhibition of
ATF-1 activation, whereas activation of CREB by VIP upon
PDE inhibition augments IL-10 production in a cell- and
stimulus-specific manner.
Treatment of RA by neuropeptides such as VIP alone may
not be efficacious but may be useful in combination with a
PDE inhibitor. This, however, cannot be explained wholly
by a failure to elevate cAMP, as treatment with dibutyryl
cAMP and other cAMP-elevating drugs alone failed to
induce monocyte, macrophage, and T-cell IL-10 but could,
however, downregulate TNF-α upon stimulation and spon-
taneous TNF-α production by RA-SMCs. In the presence
of an exogenous stimulus such as LPS for monocytes and
macrophages and PMA/ionomycin for T cells, TNF-α pro-
duction was downregulated whereas IL-10 was relatively
unaffected. Of particular interest is the observation that
elevation of cAMP augments macrophage IL-10 produc-
tion with a concomitant potent inhibition of TNF-α upon
PKC activation by PMA/ionomycin. This augmentation was
not observed for VIP alone; however, treatment with VIP
and simultaneous PDE inhibition by rolipram did augment
IL-10 production by PMA/ionomycin-stimulated macro-
phages. This augmentation response is specific, as it was
not reproducible in LPS-stimulated macrophages and
stimulated T cells. This suggests that there is a complex
relationship between the PKC and cAMP-dependent PKA
pathways regulating macrophage IL-10 production and
suggests that IL-10 augmentation is specific not only to
cell type but also to the stimulus.
Comparing these data with those found in the mouse, the
augmentation of IL-10 and downregulation of TNF-α and
IFN-γ results in a Th2 cytokine profile that is dependent on
cell types present, differentiation status, and the activation
stimulus encountered. The effectiveness of VIP as an anti-
inflammatory agent in vivo for CIA in the mouse contrasts
starkly with in vitro human data. This may be due to differ-
ences between murine and human cells but it is also pos-
sible that VIP activates regulatory circuits in vivo that are
not seen in vitro. The differences in VIP sensitivity
between these two systems requires further work and is
currently being investigated in our laboratory. Cyclic-AMP
levels can be raised by increasing the activity of adenylate
cyclase or by decreasing the activity of phosphodi-
esterases. In the light of the observation that a physiologi-
cal activator of adenylate cyclase, like VIP, failed to
modulate cytokine production by RA synovial cells, proba-
bly due to high PDE activity in these cells, our findings
suggest that a PDE inhibitor is more likely to be effective
in human RA than an activator of adenylate cyclase.
However, the possibility of a combined approach using
VIP together with a PDE inhibitor merits further investiga-
tion.
Conclusion
This report has demonstrated that, in humans, VIP is rela-
tively ineffective as an anti-inflammatory mediator capable
of augmenting IL-10 while concurrently inhibiting TNF-α
production. This, however, is specific to cell type and to
the stimulus and is dependent on endogenous PDE activ-
ity. Macrophages stimulated by phorbol ester in the pres-
ence of the PDE-resistant dibutyryl cAMP augment IL-10
and strongly suppress TNF-α. No such modulation of anti-
inflammatory IL-10 was observed in T cells or
macrophages stimulated by LPS. These data suggest effi-
cacy for a combination of VIP and a phosphodiesterase
inhibitor.
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